These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38110004)

  • 1. Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score.
    Hahn M; Herber A; Berg T; Seehofer D; van Bömmel F
    J Hepatol; 2024 Jun; 80(6):e271-e272. PubMed ID: 38110004
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
    Norman JS; Mehta N
    J Hepatol; 2024 Jun; 80(6):e273-e274. PubMed ID: 38346579
    [No Abstract]   [Full Text] [Related]  

  • 3. GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation.
    Qiao W; Li J; Xiong Y; Zheng J; Jin R; Hu C
    J Cancer Res Clin Oncol; 2024 May; 150(5):241. PubMed ID: 38713414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.
    Chaiteerakij R; Zhang X; Addissie BD; Mohamed EA; Harmsen WS; Theobald PJ; Peters BE; Balsanek JG; Ward MM; Giama NH; Moser CD; Oseini AM; Umeda N; Venkatesh S; Harnois DM; Charlton MR; Yamada H; Satomura S; Algeciras-Schimnich A; Snyder MR; Therneau TM; Roberts LR
    Liver Transpl; 2015 May; 21(5):599-606. PubMed ID: 25789635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
    Norman JS; Li PJ; Kotwani P; Shui AM; Yao F; Mehta N
    J Hepatol; 2023 Dec; 79(6):1469-1477. PubMed ID: 37683735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.
    Jiang T; Zhang XS; Pan F; Lyu SC; Wang J; Huang MX; He Q; Lang R
    Medicine (Baltimore); 2021 Jul; 100(26):e26487. PubMed ID: 34190174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
    Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
    Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
    Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
    Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy.
    Toyoda H; Kumada T; Tada T; Ito T; Maeda A; Kaneoka Y; Kagebayashi C; Satomura S
    Cancer Med; 2014 Jun; 3(3):643-51. PubMed ID: 24591342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
    Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
    Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
    Tayob N; Kanwal F; Alsarraj A; Hernaez R; El-Serag HB
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):415-423.e4. PubMed ID: 35124267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.
    Huang C; Xiao X; Zhou L; Chen F; Wang J; Hu X; Gao C;
    J Clin Lab Anal; 2023 Dec; 37(23-24):e24990. PubMed ID: 38063322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
    Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
    Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Importance of AFP in Liver Transplantation for HCC.
    Özdemir F; Baskiran A
    J Gastrointest Cancer; 2020 Dec; 51(4):1127-1132. PubMed ID: 32845425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
    Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma.
    Schraiber LDS; de Mattos AA; Zanotelli ML; Cantisani GPC; Brandão ABM; Marroni CA; Kiss G; Ernani L; Marcon PDS
    Medicine (Baltimore); 2016 Jan; 95(3):e2478. PubMed ID: 26817881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
    Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
    Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.